Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Research output: Contribution to journalJournal articleResearchpeer-review

  • Uffe Høgh Olesen
  • Jakob Gramstrup Petersen
  • Antje Garten
  • Wieland Kiess
  • Jun Yoshino
  • Shin-Ichiro Imai
  • Mette Knak Christensen
  • Peter Fristrup
  • Annemette Vinding Thougaard
  • Björkling, Fredrik
  • Peter Buhl Jensen
  • Søren Jensby Nielsen
  • Maxwell Sehested
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
Original languageEnglish
JournalBMC Cancer
Pages (from-to)677
Number of pages13
Publication statusPublished - 10 Dec 2010

ID: 32331205